A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE002 (USA) · Dr. Nolan
consented 2022-12-16
AEs
4
Serious
1
Dropout signal
–
Adverse events
mild
assessed
Grade 1 Hypothyroidism — outcome: RECOVERED/RESOLVED; onset 2023-03-26 (study day 94); relationship: not assessed
severe
serious
assessed
Grade 4 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-05-23 (study day 152); relationship: N; serious criteria: life-threatening
mild
assessed
Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-06-27 (study day 187); relationship: not assessed
moderate
assessed
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-03-17 (study day 451); relationship: not assessed
Data queries
No data queries.